Product Details
Product Name:
SR8278 |
CAS No.:
1254944-66-5 |
Purity:
99.44% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | SR8278 |
Description | SR8278 is an REV-ERBα antagonist(EC50 = 0.47 μM), blocking activation of the receptor by the synthetic agonist GSK 4112 |
In vitro | SR8278 stimulates the expression of two REV-ERBα target genes involved in the regulation of glucose production, glucose 6-phosphatase and phosphoenolpyruvate carboxykinase, in liver cells[1] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (138.32 mM,), Sonication is recommended.
|
Keywords | SR-8278 | SR 8278 | Duchenne muscular dystrophy | SR8278 | inhibit | metabolism | biological rhythm | Alzheimer's disease | neurosurgery | Inhibitor | REV-ERBα | REV-ERB |
Related Compound Libraries | Nuclear Receptor Compound Library | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:6601-66-7
$54.00 / 1mg
-
CAS:34620-77-4
$110.00 / 20mg
-
CAS:908112-43-6
$41.00 / 1mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |